Neoleukin Therapeutics, Inc. AQXP Balance Sheet

Neoleukin therapeutics, inc. (AQXP)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13
Assets
Current assets:
Cash and cash equivalents
139,417	143,093	66,306	72,700	74,169	76,928	86,731	99,130	66,610	52,032	47,105	27,147	20,916	32,301	86,225	22,470	35,691	39,526	109,373	14,916	14,283	14,906	15,869	17,896	52,918	11,006
Short-term investments (Note 13)
-	-	-	-	-	-	0	3,007	26,050	56,053	72,590	104,130	100,665	70,758	59,711	44,089	33,024	34,956	8,038	14,109	20,135	24,191	-	-	-	2,820
Receivables, prepayments and deposits
236	503	1,276	509	662	237	562	1,104	1,563	740	878	915	855	426	676	1,090	772	314	-	-	-	-	-	-	-	-
Short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,134	17,989	2,714	-
Accounts and other amounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	72	57	65	76	33	66	27
Prepayments and deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	505	578	547	139	-	-	-	63
Prepayments and deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	283	424	547	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87	-	-	-	-	-	1,377
Total current assets
139,653	143,596	67,582	73,209	74,831	77,165	87,293	103,241	94,223	108,825	120,573	132,192	122,436	103,485	146,612	67,649	69,487	74,796	117,935	29,762	35,022	39,301	40,363	36,342	56,246	15,296
Property and equipment, net
2,050	2,060	1,388	318	359	400	467	781	849	905	1,029	1,092	885	849	791	387	104	89	81	85	97	105	97	116	67	75
Operating lease right-of-use assets (Note 4)
10,300	770	170	186	211	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible asset, net
513	567	622	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term prepayments and deposits
-	-	29	30	33	53	54	404	551	599	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term investments (Note 11)
-	-	-	-	-	-	-	-	-	-	-	-	20,008	50,046	16,666	32,664	38,623	38,458	0	0	0	2,003	-	16,487	-	-
Long-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,140	-	-	-
Long-term other assets
535	30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12	12	12	13	13	16	135	277
Total assets
153,051	147,023	69,791	73,743	75,434	77,618	87,814	104,426	95,623	110,329	121,602	133,284	143,329	154,380	164,069	100,700	108,214	113,343	118,028	29,859	35,131	41,422	48,615	52,963	56,449	15,649
Liabilities
Current liabilities:
Accounts payable and other liabilities
5,003	4,125	2,300	958	3,396	4,618	10,749	13,348	9,355	10,956	6,997	8,128	5,824	9,519	8,564	8,497	5,723	4,792	-	-	-	5,203	-	-	-	-
Operating lease liabilities (Note 4)
541	556	200	201	200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finance lease liabilities (Note 4)
59	62	65	-	-	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,859	3,983	4,972	-	4,571	2,826	1,220	2,350
Current portion of bank loan (Note 8)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	250
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	16	19
Total current liabilities
5,603	4,743	2,565	1,159	3,596	4,627	10,749	13,348	9,355	10,956	6,997	8,128	5,824	9,519	8,564	8,497	5,723	4,792	3,859	3,983	4,972	5,203	4,571	2,846	1,237	2,620
Redemption option on preferred stock (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	800
Accrued tax payable on preferred stock (Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,797	1,797
Bank loan (Note 8)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,036
Other liabilities (Note 4)
-	-	-	2	4	-	343	401	443	486	513	548	562	197	142	114	106	131	-	-	-	72	-	-	7	8
Non-current operating lease liabilities (Note 4)
10,182	447	205	253	292	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-current finance lease liabilities (Note 4)
146	146	146	-	-	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	313	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liabilities (Note 7)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	142	66	79	-	63	93	107	221
Total liabilities
15,931	5,336	2,916	1,414	3,892	4,946	11,092	13,749	9,798	11,442	7,510	8,676	6,386	9,716	8,706	8,611	5,829	4,923	4,001	4,049	5,051	5,275	4,635	2,939	1,352	7,484
Redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	73,858
Commitments and contingencies (Note 15)
-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	-	0
Shareholders’ equity
Share capital: (Note 5)
Common stock - $0.000001 par value - authorized, 100,000,000 as of March 31, 2020 and December 31, 2019; issued and outstanding, 38,386,160 as of March 31, 2020 and 37,996,849 as of December 31, 2019.
-	-	-	-	0	-	0	0	0	0	0	0	0	-	0	0	0	0	0	0	0	0	-	-	-	-
Preferred stock - $0.000001 par value - authorized, 5,000,000 as of March 31, 2020 and December 31, 2019; nil issued and outstanding as of March 31, 2020 and December 31, 2019.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0
Additional paid-in capital
445,291	441,216	358,303	304,625	303,837	302,759	301,922	300,886	298,974	297,459	296,429	295,214	293,783	293,111	292,405	220,905	220,419	219,986	219,637	126,383	125,904	125,567	125,297	125,064	124,713	-
Accumulated deficit
-308,171	-299,529	-291,428	-232,296	-232,295	-230,087	-225,200	-210,207	-213,125	-198,502	-182,234	-170,401	-156,635	-148,278	-137,034	-128,888	-117,987	-111,276	-105,613	-100,577	-95,827	-89,416	-81,325	-75,040	-	-65,693
Accumulated other comprehensive loss
-	-	-	-	-	-	-	-2	-24	-70	-103	-205	-205	-169	-8	72	-47	-290	3	4	3	-4	7	0	-	-
Deficit accumulated in the development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	69,616	-
Total shareholders' equity
137,120	141,687	66,875	72,329	71,542	72,672	76,722	90,677	85,825	98,887	114,092	124,608	136,943	144,664	155,363	92,089	102,385	108,420	114,027	25,810	30,080	36,147	43,979	50,024	55,097	-65,693
Total liabilities and shareholders' equity
153,051	147,023	69,791	73,743	75,434	77,618	87,814	104,426	95,623	110,329	121,602	133,284	143,329	154,380	164,069	100,700	108,214	113,343	118,028	29,859	35,131	41,422	48,615	52,963	56,449	15,649